东亚药业（605177）(605177.SH)发布公告，经公司财务部门初步测算，预计公司2025年度归属于上市 公司股东的净利润为负值，2025年度经营业绩将出现亏损。 ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares) [2]. - The main business segments include heparin sodium raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 18.048 billion yuan, with a trading volume of 87.8751 million yuan and a turnover rate of 0.57% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9]. Technical Analysis - The average trading cost of the stock is 11.62 yuan, with the current price approaching a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

Group 1 - The core viewpoint highlights the competitive advantages of Chinese CXO companies in the chemical pharmaceutical sector, particularly in talent, chemical capabilities, compliance production capacity, and intellectual property protection, which are expected to maintain a strong irreplaceability over the next five years [1] - In the biopharmaceutical sector, the revenue growth rate of CDMO companies in South Korea and Japan is higher compared to domestic counterparts, while global competition includes companies from the US and Europe, with WuXi AppTec's market share in the CRDMO field continuing to rise [1] - Two long-term factors to observe include the potential structural limitations on overseas orders for Chinese companies due to the global biopharmaceutical supply chain restructuring driven by the "biopharmaceutical alliance," and the impact of the implementation of the "Biological Safety Law" on the international business of Chinese CXO companies [1] Group 2 - The Innovation Drug ETF Guotai (517110) tracks the SHS Innovation Drug Index (931409), which selects innovative pharmaceutical companies from the Shanghai, Shenzhen, and Hong Kong markets, covering both biopharmaceuticals and chemical pharmaceuticals [2] - The index focuses on companies with outstanding R&D capabilities and excellent growth potential, reflecting the overall performance of the innovative drug industry with a significant growth-oriented investment style [2]

Core Viewpoint - The company is progressing steadily with its AI smart factory project, which was completed by the end of September last year, and is currently in the process of obtaining drug production licenses [2][4]. Group 1 - The AI smart factory of the company was completed by the end of September last year [2][4]. - The injection manufacturing project is advancing as planned [2][4]. - The company is currently handling the necessary drug production licensing matters [2][4].

Group 1 - The main market saw a net inflow of 19.18 billion yuan as of January 14 [1] - The top ten sectors with the largest capital outflows included Energy Metals (-1.365 billion yuan), Wind Power Equipment (-1.086 billion yuan), and Communication Equipment (-0.983 billion yuan) [1] - The banking sector experienced a capital outflow of 0.721 billion yuan, while the healthcare services sector saw an outflow of 0.628 billion yuan [1] Group 2 - The Energy Metals sector had a slight decline of 0.13% with a net outflow of 1.365 billion yuan, led by the company Greenmei [2] - The Wind Power Equipment sector increased by 1.61% but still faced a net outflow of 1.086 billion yuan, with major outflow attributed to Daikin Heavy Industries [2] - The Communication Equipment sector rose by 4.01% despite a net outflow of 0.983 billion yuan, primarily driven by Galaxy Electronics [2][3]

Group 1 - Eddie Pharmaceutical's stock increased by 5.12%, reaching 17.86 CNY per share, with a trading volume of 74.09 million CNY and a turnover rate of 1.02%, resulting in a total market capitalization of 7.515 billion CNY [1] - The company, established on December 15, 2009, and listed on July 20, 2020, is located in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddie Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceutical, a fund under Huatai-PineBridge holds 4.6607 million shares, accounting for 1.11% of the circulating shares, with an estimated floating profit of approximately 4.0548 million CNY [2] - The Huatai-PineBridge Medical Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY, achieving a year-to-date return of 10.43% and a one-year return of 41.9% [2] - The fund ranks 654 out of 8838 in year-to-date performance and 3211 out of 8089 in one-year performance, with a cumulative return of 171.57% since inception [2]

Group 1 - East Asia Pharmaceutical Co., Ltd. experienced a stock price increase of 7.02%, reaching 21.49 CNY per share, with a trading volume of 4.82 million CNY and a turnover rate of 0.20%, resulting in a total market capitalization of 2.465 billion CNY [1] - The company, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The main revenue composition includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), other products (5.05%), and additional (supplementary) products (4.46%) [1] Group 2 - Noan Fund's Noan Multi-Strategy Mixed A (320016) entered the top ten circulating shareholders of East Asia Pharmaceutical, holding 811,700 shares, which is 0.72% of the circulating shares, with an estimated floating profit of approximately 1.1445 million CNY [2] - The Noan Multi-Strategy Mixed A fund was established on August 9, 2011, with a current scale of 1.855 billion CNY, achieving a year-to-date return of 5.21% and a one-year return of 88.18% [2] - The fund manager, Kong Xianzheng, has a tenure of 5 years and 50 days, with the fund's total asset size at 5.608 billion CNY, achieving a best return of 93.39% and a worst return of -16.74% during his tenure [3]

Market Overview - On January 13, major indices in China experienced collective adjustments, with the Shenzhen Component Index falling over 1% and the ChiNext Index dropping nearly 2%. The Shanghai Composite Index closed down 0.64%, the Shenzhen Component Index down 1.37%, and the ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets reached 3.65 trillion yuan, an increase of 49.6 billion yuan compared to the previous trading day [1] - In the U.S. stock market, the three major indices also declined on January 13. The Dow Jones Industrial Average fell by 398.21 points to close at 49,191.99, a decrease of 0.80%. The S&P 500 Index dropped by 13.53 points to 6,963.74, down 0.19%, while the Nasdaq Composite Index decreased by 24.03 points to 23,709.87, a decline of 0.10% [1] Sector Performance - In the Chinese market, over 3,700 stocks declined, with the AI application concept sector rising against the trend, seeing over ten constituent stocks hitting the daily limit up. The AI medical concept remained active, while the power grid equipment sector strengthened in the afternoon. The retail sector also showed active performance. Conversely, the commercial aerospace and controllable nuclear fusion sectors experienced significant declines [1] - In the U.S., the performance of major indices reflected a general downward trend, indicating a cautious market sentiment [1] Commodity Prices - International oil prices rose on January 13. The price of light crude oil futures for February delivery on the New York Mercantile Exchange increased by $1.65 to $61.15 per barrel, a rise of 2.77%. The March delivery Brent crude oil futures price rose by $1.60 to $65.47 per barrel, an increase of 2.51% [2] Policy and Regulatory Updates - The Ministry of Commerce of China announced the continuation of anti-dumping duties on imported solar-grade polysilicon from the U.S. and South Korea, effective from January 14, 2026, for a period of five years [2] - The Ministry of Industry and Information Technology issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, aiming for significant progress in platform development and resource connectivity by 2028 [3][4] Company-Specific Developments - The approval of NVIDIA to export its H200 AI chips to China is expected to restart shipments to Chinese customers. This decision will be overseen by the U.S. Department of Commerce, which will also impose a fee of approximately 25% on the related transactions [7]

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到公司控股股东及实际控制人王俊民先生的 通知，获悉王俊民先生所持有本公司的部分股份质押展期，具体事项如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-009 海思科医药集团股份有限公司 关于控股股东部分股份质押展期的公告 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： ■ 三、备查文件 中国证券登记结算有限责任公司证券质押及司法冻结明细表。 特此公告。 海思科医药集团股份有限公司董事会 2026年01月14日 一、股东股份质押展期的基本情况 ■ 本次质押股份未负担重大资产重组等业绩补偿义务。 二、股东股份累计质押的情况 ...

重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月13日 (二)股东会召开的地点：浙江省仙居县现代工业集聚区丰溪西路9号公司行政楼会议室现场结合线上方 式 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 表决情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，董事长胡健先生主持，会议以现场投票结合网络投票的方式进行表决，会 议的召集、召开和表决方式符合《公司法》、《上市公司股东会议事规则》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事8人，列席8人 2、公司董事会秘书兼财务负责人郭军锋先生列席会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于募集资金投资项目结项、调整投资规模，并将节余募集资金永久补充流动资金的议 案 审议结果：通过 2、律师见证结论意见： 本次股东会的召集、召开程序符合《公 ...